Research map: Comparative effectiveness of sodium–glucose cotransporter-2 versus dipeptidyl peptidase-4 inhibitors on all-cause mortality in type 2 diabetes: a multinational propensity score–matched cohort study

Back to the article

Papers in this map

  1. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes · Bernard Zinman · 2015 · 12293 citations · Cited by this paper
  2. A clinical prediction model for beta cell monogenetic diabetes in Chinese patients with early-onset type 2 diabetes · 2026 · Related
  3. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045 · Hong Sun · 2021 · 10322 citations · Cited by this paper
  4. Is Omnipod 5 cost effective for the management of type 1 diabetes among adults in France? · 2025 · Related
  5. Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association · Emelia J. Benjamin · 2019 · 9246 citations · Cited by this paper
  6. No association between carbohydrate-counting knowledge and disordered eating behaviors in adults with type 1 diabetes · 2026 · Related
  7. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes · Bruce Charles Neal · 2017 · 7911 citations · Cited by this paper
  8. "Usefulness of continuous interstitial glucose in diabetic patient undergoing hemodialysis · 2025 · Related
  9. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction · John J.V. McMurray · 2019 · 7146 citations · Cited by this paper
  10. Telemedicine-based diabetic retinopathy screening in patients over 70 Years: a French cohort study within the OPHDIAT network · 2026 · Related
  11. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes · Stephen D. Wiviott · 2018 · 6475 citations · Cited by this paper
  12. Impact of high intensity physical activity compared to routine counseling on renal function decline in patients with type 2 diabetes at high risk for kidney disease - the ACTIDIANE randomized controlled trial · 2026 · Related
  13. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy · Vlado Perkovic · 2019 · 6222 citations · Cited by this paper
  14. Pancreatic polypeptide in patients with type 1 diabetes and exocrine failure or chronic pancreatitis. The DIAPP study · 2025 · Related
  15. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) · Melanie J. Davies · 2018 · 3566 citations · Cited by this paper
  16. Ulcer topography matters: hindfoot versus forefoot outcomes in first-time diabetic foot ulcer · 2025 · Related
  17. Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus · Benjamin M. Scirica · 2013 · 3507 citations · Cited by this paper
  18. Comparative cardiovascular effectiveness of GLP-1RAs versus DPP-4is in dialysis patients with type 2 diabetes: a target trial emulation · 2026 · Related
  19. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial · Hertzel C. Gerstein · 2019 · 3179 citations · Cited by this paper
  20. Handgrip strength cut-off points for identifying French adults at risk of type 2 diabetes · 2025 · Related
  21. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes · Jennifer B. Green · 2015 · 2619 citations · Cited by this paper
  22. Outcome of Heart Failure with Preserved Ejection Fraction in a Population-Based Study · R. Sacha Bhatia · 2006 · 1975 citations · Cited by this paper
  23. Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs · Mikhail Kosiborod · 2017 · 821 citations · Cited by this paper
  24. Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association · Caroline S. Fox · 2015 · 497 citations · Cited by this paper
  25. Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs · Mikhail Kosiborod · 2018 · 472 citations · Cited by this paper
  26. The Relationship of Sugar to Population-Level Diabetes Prevalence: An Econometric Analysis of Repeated Cross-Sectional Data · Sanjay Basu · 2013 · 438 citations · Cited by this paper
  27. Incretin-Based Therapies for Type 2 Diabetes Mellitus: Properties, Functions, and Clinical Implications · Michael Albrecht Nauck · 2010 · 293 citations · Cited by this paper
  28. A comprehensive review of methodologies and application to use the real-world data and analytics platform TriNetX · Ralf Joachim Ludwig · 2025 · 241 citations · Cited by this paper
  29. Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial · Jacob Allen Udell · 2014 · 165 citations · Cited by this paper
  30. Comparative Effectiveness of SGLT2 Inhibitors, GLP-1 Receptor Agonists, DPP-4 Inhibitors, and Sulfonylureas on Risk of Kidney Outcomes: Emulation of a Target Trial Using Health Care Databases · Yan Xie · 2020 · 163 citations · Cited by this paper
  31. Mortality Reduction with Influenza Vaccine in Patients with Pneumonia Outside “Flu” Season · Dean T. Eurich · 2008 · 107 citations · Cited by this paper
  32. Comparing Effectiveness and Safety of SGLT2 Inhibitors vs DPP-4 Inhibitors in Patients With Type 2 Diabetes and Varying Baseline HbA 1c Levels · Elvira D’Andrea · 2023 · 100 citations · Cited by this paper
  33. The role of SGLT2 inhibitors in managing type 2 diabetes · Velen Tat · 2018 · 23 citations · Cited by this paper
  34. Esketamine Combined With SSRI or SNRI for Treatment-Resistant Depression · Antonio DEL CASALE · 2025 · 23 citations · Cited by this paper
  35. The long‐term efficacy and safety of DPP‐IV inhibitors monotherapy and in combination with metformin in 18 980 patients with type‐2 diabetes mellitus—a meta‐analysis · Xia Liu · 2014 · 19 citations · Cited by this paper
  36. Denosumab, for osteoporosis, reduces the incidence of type 2 diabetes, risk of foot ulceration and all‐cause mortality in adults, compared with bisphosphonates: An analysis of real‐world, cohort data, with a systematic review and meta‐analysis · Alex E. Henney · 2024 · 18 citations · Cited by this paper
  37. Enhanced renoprotective effects of combined glucagon‐like peptide‐1 receptor agonists and sodium‐glucose cotransporter 2 inhibitors in type 2 diabetes mellitus: Real‐world evidence · Jian‐Yu Jhu · 2024 · 16 citations · Cited by this paper
  38. Dipeptidyl peptidase-4 inhibitors as new tools for cardioprotection · Marina R. Rankovic · 2020 · 10 citations · Cited by this paper
  39. Cardiovascular safety of therapies for type 2 diabetes · Puneet Kumar Gupta · 2016 · 9 citations · Cited by this paper

Source: OpenAlex (CC0)